| Literature DB >> 27055100 |
Peter Pushko1, Igor S Lukashevich2, Scott C Weaver3, Irina Tretyakova1.
Abstract
A novel vaccine platform uses DNA immunization to launch live-attenuated virus vaccines in vivo. This technology has been applied for vaccine development against positive-strand RNA viruses with global public health impact including alphaviruses and flaviviruses. The DNA-launched vaccine represents the recombinant plasmid that encodes the full-length genomic RNA of live-attenuated virus downstream from a eukaryotic promoter. When administered in vivo, the genomic RNA of live-attenuated virus is transcribed. The RNA initiates limited replication of a genetically defined, live-attenuated vaccine virus in the tissues of the vaccine recipient, thereby inducing a protective immune response. This platform combines the strengths of reverse genetics, DNA immunization and the advantages of live-attenuated vaccines, resulting in a reduced chance of genetic reversions, increased safety, and improved immunization. With this vaccine technology, the field of DNA vaccines is expanded from those that express subunit antigens to include a novel type of DNA vaccines that launch live-attenuated viruses.Entities:
Keywords: DNA vaccine; Venezuelan equine encephalitis; alphavirus; chikungunya; flavivirus; live-attenuated vaccine; yellow fever
Mesh：
Substances：
Year: 2016 PMID： 27055100 PMCID： PMC5033646 DOI： 10.1080/14760584.2016.1175943
Source DB: PubMed Journal: Expert Rev Vaccines ISSN： 1476-0584 Impact factor: 5.217